Zacks Investment Research cut shares of Reneuron Gp (OTCMKTS:RNUGF) from a buy rating to a hold rating in a research report sent to investors on Saturday.

According to Zacks, “ReNeuron Group plc is involved in the development of cell-based therapies. Its therapeutic candidate is CTX stem cell therapy for the treatment of patients left disabled by the effects of a stroke which are in clinical development phase. ReNeuron Group plc is headquartered in Pencoed, the United Kingdom. “

Shares of Reneuron Gp (OTCMKTS RNUGF) opened at $0.02 on Friday. Reneuron Gp has a 12 month low of $0.02 and a 12 month high of $0.05.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at

Reneuron Gp Company Profile

ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company’s lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase III clinical trial for the treatment of patients left disabled by the effects of a stroke, as well as that has been completed Phase I clinical trial to treat critical limb ischaemia, a side effect of diabetes.

Get a free copy of the Zacks research report on Reneuron Gp (RNUGF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Reneuron Gp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneuron Gp and related companies with's FREE daily email newsletter.